Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Following reports of patient deaths and serious injuries, the US Food and Drug Administration (FDA) on Tuesday cautioned healthcare providers against using Medtronic's NavLock Tracker with instruments not cleared to be used with the device.
The NavLock tracker is an accessory to Medtronic's StealthStation surgical navigation system that is intended to be used to enable instrument navigation during spinal fusion and other procedures.
While FDA has cleared other devices, including instruments manufactured by Alphatec Spine, Globus Medical and Orthofix, for use with both the StealthStation and the NavLock Tracker, Medtronic says the NavLock Tracker should only be used with other Medtronic devices.
In updated labeling for the device, Medtronic says "the NavLock Tracker is designed and tested for use only with Medtronic instruments [and] should only be used with Medtronic instruments."
In total, FDA has identified 196 medical device reports linked to the NavLock Tracker since 2013. While the majority of the reports deal with malfunctions and do not reference the use of third-party instruments, the two reported deaths and a disproportionate number of reported injuries indicate that one or more third-party instrument was used during the procedure.
However, FDA makes it clear that the two patient deaths happened after a procedure involving the use of third-party surgical stereotaxic navigation instruments that were not cleared for use with the NavLock Tracker or the StealthStation.
And, the agency notes, it is unable to determine if, or to what degree, the use of third-party instruments led to the adverse events due to the limited information included in the reports.
"FDA recognizes that the contributing factors associated with accuracy and precision problems when using stereotaxic navigation systems are multifactorial," the agency writes.
As such, the agency is recommending against using d